Valneva to Participate in Goldman Sachs Eleventh Annual Biotech Symposium
01 September 2021 - 6:15PM
Saint-Herblain
(France),
September 1,
2021 – Valneva SE (Nasdaq: VALN; Euronext
Paris: VLA), a specialty vaccine company, today announced that its
senior management will participate in 1-on-1 meetings with
institutional investors at the Goldman Sachs Eleventh Annual
Biotech Symposium on September 7, 2021.
Valneva’s Chief Executive Officer Thomas
Lingelbach and acting Chief Financial Officer David Lawrence will
notably provide an update on the Company’s late stage vaccine
candidates against Lyme disease (VLA15), COVID-19 (VLA2001) and
chikungunya (VLA1553).
Partnered with Pfizer (NYSE: PFE), VLA15 is the
only Lyme disease vaccine in clinical development worldwide while
VLA2001 is the only inactivated vaccine candidate in clinical
trials against COVID-19 in Europe and VLA1553 is the only
single-shot chikungunya vaccine candidate in Phase 3 clinical
trials.
To request a meeting at the event, please
contact your representative at Goldman Sachs.
About Valneva SEValneva is a
specialty vaccine company focused on the development and
commercialization of prophylactic vaccines for infectious diseases
with significant unmet medical need. The Company takes a highly
specialized and targeted approach to vaccine development, beginning
with the identification of deadly and debilitating infectious
diseases that lack a prophylactic vaccine solution and for which
there are limited therapeutic treatment options. It then applies
its deep understanding of vaccine science, including its expertise
across multiple vaccine modalities, as well as its established
vaccine development capabilities, to develop prophylactic vaccines
to address these diseases. The Company has leveraged its expertise
and capabilities both to successfully commercialize two vaccines
and to rapidly advance a broad range of vaccine candidates into and
through the clinic, including candidates against Lyme disease, the
chikungunya virus and COVID-19.
Valneva Investor and Media ContactsLaetitia
Bachelot-FontaineDirector, Investor Relations & Corporate
CommunicationsM +33 (0)6 4516
7099investors@valneva.com |
Joshua Drumm, Ph.D.VP, Global Investor RelationsM +001
917 815 4520joshua.drumm@valneva.com |
|
|
- 2021_09_01_VLA_GS_PR_EN_Final
Valneva (EU:VLA)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Valneva (EU:VLA)
Historical Stock Chart
Von Apr 2023 bis Apr 2024